Whitwell J L, Boeve B F, Weigand S D, Senjem M L, Gunter J L, Baker M C, DeJesus-Hernandez M, Knopman D S, Wszolek Z K, Petersen R C, Rademakers R, Jack C R, Josephs K A
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Eur J Neurol. 2015 May;22(5):745-52. doi: 10.1111/ene.12675. Epub 2015 Feb 12.
The aim of our study was to determine the utility of longitudinal magnetic resonance imaging (MRI) measurements as potential biomarkers in the main genetic variants of frontotemporal dementia (FTD), including microtubule-associated protein tau (MAPT) and progranulin (GRN) mutations and C9ORF72 repeat expansions, as well as sporadic FTD.
In this longitudinal study, 58 subjects were identified who had at least two MRI and MAPT mutations (n = 21), GRN mutations (n = 11), C9ORF72 repeat expansions (n = 11) or sporadic FTD (n = 15). A total of 198 serial MRI measurements were analyzed. Rates of whole brain atrophy were calculated using the boundary shift integral. Regional rates of atrophy were calculated using tensor-based morphometry. Sample size estimates were calculated.
Progressive brain atrophy was observed in all groups, with fastest rates of whole brain atrophy in GRN, followed by sporadic FTD, C9ORF72 and MAPT. All variants showed greatest rates in the frontal and temporal lobes, with parietal lobes also strikingly affected in GRN. Regional rates of atrophy across all lobes were greater in GRN compared to the other groups. C9ORF72 showed greater rates of atrophy in the left cerebellum and right occipital lobe than MAPT, and sporadic FTD showed greater rates in the anterior cingulate than C9ORF72 and MAPT. Sample size estimates were lowest using temporal lobe rates in GRN, ventricular rates in MAPT and C9ORF72, and whole brain rates in sporadic FTD.
These data support the utility of using rates of atrophy as outcome measures in future drug trials in FTD and show that different imaging biomarkers may offer advantages in the different variants of FTD.
我们研究的目的是确定纵向磁共振成像(MRI)测量作为额颞叶痴呆(FTD)主要基因变异潜在生物标志物的效用,这些基因变异包括微管相关蛋白tau(MAPT)和原纤维蛋白(GRN)突变、C9ORF72重复扩增,以及散发性FTD。
在这项纵向研究中,确定了58名受试者,他们至少有两次MRI检查结果,且存在MAPT突变(n = 21)、GRN突变(n = 11)、C9ORF72重复扩增(n = 11)或散发性FTD(n = 15)。共分析了198次连续的MRI测量结果。使用边界位移积分计算全脑萎缩率。使用基于张量的形态测量法计算区域萎缩率。计算样本量估计值。
所有组均观察到进行性脑萎缩,GRN组全脑萎缩率最快,其次是散发性FTD、C9ORF72和MAPT组。所有变异在额叶和颞叶的萎缩率最高,GRN组的顶叶也受到显著影响。与其他组相比,GRN组所有脑叶的区域萎缩率更高。C9ORF72组左小脑和右枕叶的萎缩率高于MAPT组,散发性FTD组前扣带回的萎缩率高于C9ORF72组和MAPT组。使用GRN组的颞叶萎缩率、MAPT组和C9ORF72组的脑室萎缩率以及散发性FTD组的全脑萎缩率时,样本量估计值最低。
这些数据支持在未来FTD药物试验中使用萎缩率作为结局指标的效用,并表明不同的成像生物标志物可能在FTD的不同变异中具有优势。